1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
The United Laboratories International Holdings Limited

The United Laboratories International Holdings Limited

ULIHF
The United Laboratories International Holdings LimitedUS flagOther OTC
1.24
USD
- -
- -
2.44BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
3.67
3.95
3.96
3.74
4.2
4.6
5.12
4.97
5.27
6.23
7.56
7.57
7.01
Basic EPS, GAAP
0.02
0.33
0.06
-0.17
0.05
0.42
0.39
0.4
0.54
0.87
1.49
1.46
1.11
Free Cash Flow per Basic Share
-0.27
0.22
0.53
0.37
0.18
0.4
0.82
0.58
0.57
0.67
0.54
0.73
0.45
Dividend per Share
- -
- -
- -
- -
- -
0.05
0.06
0.07
0.12
0.15
0.32
0.56
0.55
Book Value per Share
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
2.25
2.94
4.02
4.83
5.14
Tangible Book Value per Share
3
3.39
3.4
3.19
3.25
3.52
3.98
4.8
5.01
5.77
6.94
7.82
9.12
Basic Weighted Avg Shares
1,627
1,627
1,627
1,627
1,627
1,634
1,640
1,766
1,840
1,820
1,817
1,817
1,885
Sales/Revenue/Turnover
5,977
6,421
6,443
6,078
6,827
7,511
8,393
8,772
9,703
11,334
13,740
13,759
13,211
Operating Margin (%)
9.97
19.62
12.49
7.97
11.24
13.49
12.95
15
15.12
18.45
23.94
22.65
18.8
Depreciation Expense
449
570
688
716
790
748
676
614
621
552
566
616
650
Net Income, GAAP
38
545
92
-272
82
683
642
703
988
1,581
2,701
2,660
2,086
Effective Tax Rate (%)
94.67
- -
53.12
- -
- -
13.98
23.75
20.56
17.72
21.22
19.24
19.19
17.68
Profit Margin (%)
0.63
8.48
1.43
-4.48
1.2
9.09
7.65
8.01
10.18
13.95
19.66
19.33
15.79
Working Capital
-2,595
-1,831
-2,268
-968
976
182
2,255
3,365
3,451
5,482
7,160
7,298
8,390
LT Debt
1,692
1,730
1,194
1,839
2,992
1,591
2,423
1,303
228
1,100
1,303
2,321
2,880
Total Equity
5,065
5,573
5,626
5,347
5,442
6,122
6,672
8,612
9,340
10,609
12,748
14,435
17,475
Return on Invested Capital (%)
0.3
- -
3.34
- -
- -
8.56
7.42
9.09
10.73
13.26
18.94
15.47
10.07
Return on Capital (%)
0.81
- -
4.07
- -
- -
20.58
18.44
23.45
25.23
23.85
33.15
25.88
16.07
Return on Common Equity (%)
290.84
4,234.62
654.33
-1,787.51
536.58
4,466.06
4,180.06
4,320.37
47.48
33.32
42.72
33.1
22.59

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.39%
15.3%
21.06%
Free Cash Flow
12.11%
-0.35%
-35.63%
Net Income, GAAP
36.24%
29.66%
-21.57%
Sales/Revenue/Turnover
7.77%
8.96%
-3.99%
Total Cash Common Dividend
- -
57.3%
2.45%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
13,740
2024
- -
- -
- -
- -
13,759
2025
- -
- -
- -
- -
13,211

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.49
2024
- -
- -
- -
- -
1.46
2025
- -
- -
- -
- -
1.11

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.32
2024
- -
- -
- -
- -
0.56
2025
- -
- -
- -
- -
0.55

Company Description

APIChatGPT
CEO
Hoi Shan Tsoi
Full Time Employees
18,000
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
6 Fuk Wang Street Yuen Long Hong Kong
IPO Date
Nov 3, 2014
Website
tul.com.cn
Similar Companies
Juva Life Inc. (JUVA.CN)
Livzon Pharmaceutical Group Inc. (1513.HK)
Fusen Pharmaceutical Company Limited (1652.HK)
EuBiologics Co., Ltd. (206650.KQ)
Luoxin Pharmaceuticals Group Stock Co., Ltd. (002793.SZ)
American Green, Inc. (ERBB)
Business
The United Laboratories International Holdings Limited (3933.HK), founded in 1990 and headquartered in Yuen Long, Hong Kong, operates as a leading integrated pharmaceutical company in China, primarily engaged in the research, development, production, and sale of pharmaceuticals across intermediate products, bulk medicines, and finished products; it also produces veterinary drugs, empty capsule casings, organic fertilizers, and medical devices. The company maintains seven production bases supporting a vertically integrated model that spans antibiotics, biopharmaceuticals, and animal healthcare products, including APIs, non-antibiotics finished products such as antibiotics and capsule casings, and emerging lines in endocrine, metabolism, autoimmunity, anti-infection, and ophthalmology therapies; its sales networks reach nearly 80 countries and regions, including China (including Hong Kong), Europe, India, other Asian regions, South America, the Middle East, and beyond. Targeting human and animal health markets with over 100 R&D projects and more than 100 patents, the group recently expanded into big health via a new division offering dietary supplements, healthcare foods, nutritional supplements, medical devices, and medical aesthetic skincare products across e-commerce, pharmacy chains, and health channels. In recent developments, the company entered a strategic partnership in March 2024 with New Zealand's Riverland Foods Ltd. to introduce high-end prescription pet food into China and signed a comprehensive cooperation agreement with Sinopharm Group Co., Ltd. to enhance collaborations across industrial, supply, and innovation chains; it secured six overseas registrations for animal healthcare preparations and won a tender for human insulin procurement from Brazil's Ministry of Health. On March 24, 2025, its wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. finalized an exclusive license agreement with Novo Nordisk A/S for the self-developed Class 1 innovative drug UBT251 Injection, a GLP-1/GIP/glucagon triple receptor agonist approved for clinical trials in China and the United States targeting obesity, type 2 diabetes, and other cardiometabolic indications. The group increased R&D investment by 21.9% to RMB985.5 million in 2024, advancing eight Class 1 drugs into clinical stages and progressing bulk medicine and animal healthcare production capacity expansions, while reporting steady revenue of RMB13.76 billion for the year.